Aberdeen Group
ORKA

Aberdeen Group’s Oruka Therapeutics ORKA Stock Holding History

Aberdeen Group’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.6M Buy
646,943
+571,263
+755% +$38.1M 0.09% 189
2026
Q1 		$3.71M Hold
75,680
– – 0.01% 720
2025
Q4 		$2.29M Hold
75,680
– – ﹤0.01% 767
2025
Q3 		$1.46M Sell
75,680
-2,700
-3% -$40K ﹤0.01% 809
2025
Q2 		$879K Buy
+78,380
New +$817K ﹤0.01% 839
2024
Q3 		– Sell
-2,705
Closed -$124K – 974
2024
Q2 		$124K Hold
2,705
– – ﹤0.01% 937
2024
Q1 		$57.1K Hold
2,705
– – ﹤0.01% 942
2023
Q4 		$55.2K Buy
+2,705
New +$60.7K ﹤0.01% 956

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Aberdeen Group's ORKA Position: Q2 2026 in Review

Aberdeen Group increased its Oruka Therapeutics (ORKA) stake by 755% in Q2 2026, buying an estimated $38.1M and bringing the position to 646,943 shares worth $61.6M. The position accounts for 0.09% of the portfolio, ranked #189.

Aberdeen Group first reported a position in ORKA in Q4 2023 and has held it in 8 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Aberdeen Group held 646,943 shares of Oruka Therapeutics worth $61.6M as of Q2 2026.
  • Aberdeen Group bought 571,263 Oruka Therapeutics shares in Q2 2026, an estimated $38.1M.
  • Oruka Therapeutics made up 0.09% of Aberdeen Group's portfolio in Q2 2026, its #189 holding.
  • Aberdeen Group first reported a position in Oruka Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.